ARS Pharmaceuticals (SPRY) Profit After Tax (2020 - 2026)

ARS Pharmaceuticals has disclosed Profit After Tax across 7 years of filings, most recently posting -$60.6 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$60.6 million, down 78.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$198.0 million (down 1165.02% YoY), and the FY2025 annual result was -$171.3 million, down 2241.76% from the prior year.
• Profit After Tax came in at -$60.6 million for Q1 2026 at ARS Pharmaceuticals, down from -$41.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $49.9 million in Q4 2024 to a low of -$60.6 million in Q1 2026.
• The 5-year median for Profit After Tax is -$14.9 million (2023), against an average of -$18.4 million.
• Across the five-year window, Profit After Tax surged 796.62% in 2024 and sank 258.6% in 2025, its largest moves.
• ARS Pharmaceuticals' Profit After Tax stood at -$14.4 million in 2022, then soared by 50.32% to -$7.2 million in 2023, then jumped by 796.62% to $49.9 million in 2024, then slumped by 182.76% to -$41.3 million in 2025, then tumbled by 46.69% to -$60.6 million in 2026.
• The last three Profit After Tax figures came in at -$60.6 million (Q1 2026), -$41.3 million (Q4 2025), and -$51.2 million (Q3 2025), per Business Quant data.